The global insulin delivery devices market was valued at USD 16.42 billion in 2023 and is projected to reach USD 28.06 billion by 2030, registering a CAGR of 7.89% from 2024 to 2030. Market growth is primarily driven by the rising global prevalence of diabetes, which is increasing the need for advanced, convenient, and patient-centric diabetes management solutions. Technological advancements also play a significant role, with device innovations focusing on improving effectiveness, reducing invasiveness, and enhancing personalization for users.
The expanding geriatric population further supports market growth. Insulin delivery devices—including insulin pens, pumps, and smart insulin systems—are increasingly tailored to older adults, addressing challenges related to declining vision, reduced motor skills, and cognitive limitations. Their ease of use, dosing accuracy, and integration with digital health platforms enable better treatment adherence, improved glycemic control, and reduced complication risks. As diabetes continues to rise among older adults worldwide, this demographic presents substantial growth opportunities. Manufacturers are incorporating geriatric-friendly features such as larger displays, simplified interfaces, and minimized manual dexterity requirements, contributing significantly to wider adoption and reinforcing the importance of these devices in elderly diabetes care.
Key Market Trends & Insights
- North America accounted for the largest market share at 40.73% in 2023.
- The U.S. led the North American market in 2023.
- By product, insulin pens held the largest share at 43.68% in 2023.
- By end use, the hospitals and clinics segment is expected to record the fastest CAGR of 8.42% during the forecast period.
Download a free sample PDF of the Insulin Delivery Devices Market Intelligence Study by Grand View Research.
Market Size & Forecast
- 2023 Market Size: USD 16.42 Billion
- 2030 Projected Market Size: USD 28.06 Billion
- CAGR (2024–2030): 7.89%
- Leading Region (2023): North America
Competitive Landscape
The insulin delivery devices market is dynamic and rapidly evolving, driven by the growing global diabetic population and the demand for efficient, user-friendly insulin administration solutions. The landscape is highly competitive, with both established companies and emerging innovators expanding product portfolios to meet varied patient needs. Market leadership is influenced by product innovation, device accessibility, ease of use, and insurance coverage. Major players—including Novo Nordisk, Sanofi, and Eli Lilly—dominate due to their broad offerings and strong global presence. Meanwhile, smaller companies and startups are gaining traction with specialized products such as wearable insulin devices and smart insulin pens, intensifying competition within the space.
Prominent Companies
- Novo Nordisk A/S
- Sanofi
- Eli Lilly and Company
- Ypsomed AG
- Medtronic
- Insulet Corporation
- B. Braun SE
- Owen Mumford Ltd.
- Tandem Diabetes Care, Inc.
- BD (Becton, Dickinson and Company)
Explore Horizon Databook – the world’s most comprehensive market intelligence platform by Grand View Research.
Conclusion
The insulin delivery devices market is poised for strong growth through 2030, driven by rising diabetes prevalence, continuous technological innovation, and increasing adoption among the expanding geriatric population. As manufacturers focus on developing smarter, more intuitive, and user-friendly devices, market competitiveness will intensify, offering patients improved options for effective diabetes management. With North America leading the market and emerging technologies reshaping patient care, the sector is expected to remain a critical component of global healthcare advancements.
No comments:
Post a Comment